Results obtained in the LifEscozul™ Protocol in patient Santiago Perez.
In this interview, for theLifEscozul™(Escozul, blue scorpion venom, blue scorpion) Protocol we will learn that Santiago started with LifEscozul™ in early February 2015 and was not receiving any other treatment by personal choice.
In mid-March 2015, a CT scan showed stability of the disease at the lung level.
During the following months of 2015, Santiago's blood tests remained in normal ranges, with no change in his physical condition.
Santiago was treated under the LifEscozul™ protocol (protein active ingredient) with periodic controls and progressive dosage increases.
Learn about Santiago's evolution in his own words.
This interview was conducted by Biologist Ariel Portal for the Protocol LifEscozul™ (Escozul, blue scorpion venom, blue scorpion venom).
For any questions please write to firstname.lastname@example.org or fill out the form below.
The LifEscozul Group™ continues with this interview a cycle of interviews with our oldest patients within the LifEscozul Protocol™ ( Escozul, blue scorpion venom, blue scorpion).
LifEscozul™ is a product with a registered trademark in the USA and Ecuador and in the process of registration in more than 20 countries. It has been developed by Cuban doctors and scientists based on the antitumor active ingredient extracted from blue scorpion venom (Escozul).